Clostridium Enterocolitis
9
0
0
8
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
56%
5 trials in Phase 3/4
13%
1 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (9)
Outcomes From Hyperbaric Oxygen (HBO2) Treatment for Emerging Indications
Efficacy of Metronidazole Versus Metronidazole and Rifampin in CDAD Treatment
Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Infection
Vancomycin vs. Nitazoxanide to Treat Recurrent C. Difficile Colitis
A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C.Difficile - Associated Diarrhea
A Study of GT160-246 Versus Vancomycin in Patients With Clostridium Difficile-Associated Diarrhea
A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C. Difficile-Associated Diarrhea
Response of Clostridium Difficile Infection to Metronidazole Therapy
Association Between Response to Treatment of C. Diff Colitis and Anti-C.Diff Toxin Antibody